Antidepressants shown ineffective for bipolar depression
The Carlat Psychiatry Report, Volume 5, Number 5, May 2007
James Ellison, MD, MPH
The largest and most rigorous study to date on the treatment of bipolar depression was just published in the New England Journal of Medicine. The study, conducted as part of the NIMH-funded Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD), enrolled a total of 366 subjects with either bipolar I or II disorder during a major depressive episode.
James Ellison, MD
Clinical Director, Geriatric Psychiatry Program, McLean Hospital Associate Professor of Psychiatry, Harvard Medical School
Dr. Ellison has disclosed that he is on the speaker’s bureaus of Pfizer, Inc., Wyeth, Inc., and Forest Laboratories, and has spoken about Aricept, Effexor XR, Lexapro, and Namenda. He has received between $5,000 and $20,000 over the last 12 months for these activities. He has also received research grant support, via McLean hospital, from GlaxoSmithKline for research on Avandia (rosiglitazone). Dr. Carlat has reviewed and edited the content of this interview to ensure a balanced and unbiased presentation.